© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Brukinsa

Brukinsa’s Approval Improves Targeted Treatment for Leukemia

Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.

Behind the Study That Led to FDA Approval of Brukinsa for Leukemia and Lymphoma

The Dana-Farber led ALPINE trial looked at the drug in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Red and white blood cells

Brukinsa Beats Imbruvica for Chronic Lymphocytic Leukemia

The newer targeted therapy zanubrutinib works better and has fewer side effects than the older ibrutinib.

Can Cancer Drugs Be Used to Treat COVID-19?

Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.

FDA Approves New Treatment for Mantle Cell Lymphoma

Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
Advertisement

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.